Altravax has developed the ParaClin™ approach to early-stage vaccine testing in humans that benefits from the recent changes in regulatory guidelines. The ParaClin™ protocols allow lead candidates to be selected based on human data and substantially increases the likelihood of successful product development. By testing multiple vaccine candidates in humans under favorable regulatory and budgetary conditions, the final selection of a lead product for further development is based on the all-important clinical evaluation. In this way, Altravax is well positioned to develop a new generation of high-value vaccines for the growing market of preventative and therapeutic interventions for infectious diseases.